Mirum Pharmaceuticals, Inc. cotiza a 80.75 USD y tiene una capitalización bursátil de $5.2B. En los últimos 12 meses ha facturado $618M con un margen de flujo de caja libre del 10.5%. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that i…
| Periodo | 2026-11 | 2026-08 | 2026-05 | 2026-02 |
|---|---|---|---|---|
| Real | — | $-0.80 | $-1.08 | $-0.12 |
| Estimado | $-0.42 | $-0.75 | $-0.35 | $0.06 |
| Sorpresa | — | -6.7% | -208.6% | -300.0% |
| Métrica | MIRM | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.0% | — |
| Operating Margin | -4.3% | -38.6% | +34.4% |
| Net Margin | -4.5% | -33.6% | +29.1% |
| FCF Margin | 10.5% | -13.9% | +24.4% |
| ROE | -7.4% | -40.4% | +33.0% |
| ROA | -2.8% | -32.0% | +29.2% |
| Current Ratio | 2.67 | 2.84 | -0.17 |
| Debt / Equity | — | 0.28 | — |